Adaptimmune Therapeutics (ADAP) Tops Q3 EPS by 14c

Adaptimmune Therapeutics (NASDAQ: ADAP) reported Q3 EPS of ($0.03), $0.14 better than the analyst estimate of ($0.17). Revenue for the quarter came in at $7.3 million versus the consensus estimate of $14.41 million.

For earnings history and earnings-related data on Adaptimmune Therapeutics (ADAP) click here.

You May Also Be Interested In

• onsemi downgraded by TD Cowen after Synaptics deal clouds growth story
• Argus starts SpaceX at Hold, sees record IPO as a multi-year re-rating challenge
• Apogee Enterprises (APOG) Tops Q1 EPS by 16c, Beats on Revenue; Offers FY27 Guidance